Skip to main content

Table 3 Average monthly total costs (JPY)

From: Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy

 

Total costs (mean)

95 % CI

Minimum

25th percentile

Median

75th percentile

Maximum

Overall treatment period (n = 30)

308,363

(258,792–357,933)

152,345

208,653

270,328

340,179

637,299

 First-line treatment (n = 30)

256,149

(207,992–304,307)

149,816

186,293

208,555

261,922

637,299

 Second-line treatment (n = 20)

518,897

(431,290–606,504)

280,977

348,454

431,758

650,541

925,339

 Third-line treatment (n = 8)

416,251

(188,316–644,185)

141,582

162,033

297,117

600,389

1,056,666

 Oxaliplatin-based regimens (n = 13)

418,463

(357,413–479,513)

280,977

339,667

399,767

444,406

635,115

 Irinotecan-based regimens (n = 31)

215,499

(188,359–242,639)

141,867

171,990

207,516

223,415

567,549

 Regimens including molecular targeted agents (n = 11)

705,460

(586,733–824,187)

411,384

597,586

710,434

822,972

1,056,666

  1. Costs during the overall treatment period were calculated from the beginning of treatment to the end of treatment and were discounted by 3 % after the twelfth month
  2. The costs of first-line, second-line, and third-line treatments were calculated until the end of each treatment and were discounted by 3 % after the twelfth month
  3. The costs of each regimen group were calculated until the twelfth month and were not discounted